Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
This review highlights the atherogenic and thrombogenic risks of elevated Lp(a) and emphasizes the need for aggressive LDL-lowering and aspirin therapy pending the development of targeted Lp(a)-lowering drugs.
Lipoprotein(a) (Lp(a)) was first described by K. Berg and is known for more than 50 years. It is an interesting particle and combines the atherogenic properties of low-density lipoprotein (LDL)-cholesterol as well as the thrombogenic properties of plasminogen inactivation. However, due to technical problems and publication of negative trials the potential role of Lp(a) in atherosclerosis was severely underestimated. In recent years our understanding of the function and importance of Lp(a) improved. Interventional trials with niacin failed to demonstrate any benefit of lowering Lp(a); however, several studies confirmed the residual cardiovascular disease (CVD) risk of elevated Lp(a). LDL/Lp(a) apheresis is able to lower Lp(a) and some new drugs under development should help us to lower Lp(a) in the near future. It will be important to follow this with hard endpoint trials. Until then most clinicians recommend the use of an aggressive LDL-lowering approach in patients with high Lp(a). Since most of these patients with high Lp(a) might have manifested atherosclerosis anyway, we would also consider the use of acetylsalicylic acid.
No takes yet. Share an insight, caveat, or question.
Kurt et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: